Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).
Humans
Female
Middle Aged
Male
Self Report
Prospective Studies
Quality of Life
Analgesics, Opioid
Rheumatology
Antirheumatic Agents
/ therapeutic use
Australia
/ epidemiology
Arthritis, Rheumatoid
/ complications
Cohort Studies
Pain
/ drug therapy
Prednisolone
/ therapeutic use
Outcome Assessment, Health Care
arthritis, rheumatoid
epidemiology
patient reported outcome measures
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
23
12
2022
accepted:
07
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
To determine distinct trajectories of self-reported pain-related health status in rheumatoid arthritis (RA), their relationship with sociodemographic factors and medication use. 988 Australian Rheumatology Association Database participants with RA (71% female, mean age 54 years, mean disease duration 2.3 years) were included. Distinct multi-trajectories over 15-year follow-up for five different self-reported pain-related health outcome measures (Health Assessment Questionnaire Disability Index, visual analogue scores for pain, arthritis, global health and the Assessment of Quality of Life utility index) were identified using latent variable discrete mixture modelling. Random effects models were used to determine associations with medication use and biologic therapy modification during follow-up. Four, approximately equally sized, pain/health status groups were identified, ranging from 'better' to 'poorer', within which changes over time were relatively small. Important determinants of those with poorer pain/health status included female gender, obesity, smoking, socioeconomic indicators and comorbidities. While biologic therapy use was similar between groups during follow-up, biologic therapy modifications (p In the absence of disease activity information, distinct trajectories of varying pain/health status were seen from the outset and throughout the disease course in this RA cohort. More biologic therapy modifications and greater use in anti-inflammatories, opioids and prednisolone were seen in those with poorer pain/health status, reflecting undesirable lived experience of persistent pain in RA.
Identifiants
pubmed: 37507204
pii: rmdopen-2022-002962
doi: 10.1136/rmdopen-2022-002962
pmc: PMC10391633
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Antirheumatic Agents
0
Prednisolone
9PHQ9Y1OLM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Arthritis Rheum. 1980 Feb;23(2):137-45
pubmed: 7362664
Ann Rheum Dis. 1992 Jan;51(1):140
pubmed: 1540024
Rheumatology (Oxford). 2022 Apr 11;61(4):1496-1509
pubmed: 34270700
Curr Osteoporos Rep. 2018 Oct;16(5):603-610
pubmed: 30128836
Semin Arthritis Rheum. 2019 Dec;49(3):351-357
pubmed: 31280936
Ann Rheum Dis. 2023 Jan;82(1):74-80
pubmed: 36280238
Ann Rheum Dis. 2012 Oct;71(10):1702-5
pubmed: 22736085
Ann Intern Med. 2019 Jan 1;170(1):ITC1-ITC16
pubmed: 30596879
Circulation. 2002 Jul 2;106(1):5-7
pubmed: 12093759
Qual Life Res. 2007 May;16(4):661-73
pubmed: 17268926
Ann Rheum Dis. 2021 Jan;80(1):31-35
pubmed: 33004335
Arthritis Care Res (Hoboken). 2012 Feb;64(2):190-6
pubmed: 21972106
Ann Rheum Dis. 2008 Dec;67(12):1710-5
pubmed: 18218667
Qual Life Res. 1999 May;8(3):209-24
pubmed: 10472152
Eur J Pain. 2020 Nov;24(10):1979-1989
pubmed: 32841455
SAGE Open Med. 2017 Jun 07;5:2050312117713647
pubmed: 28611920
Rheumatology (Oxford). 2020 Nov 1;59(11):3458-3467
pubmed: 32375173
Rheumatology (Oxford). 2003 Aug;42(8):995-1000
pubmed: 12730516
Arthritis Care Res (Hoboken). 2018 Mar;70(3):369-378
pubmed: 28544615
J Rheumatol. 2023 Jun;50(6):741-747
pubmed: 36642431
Ann Rheum Dis. 2019 Oct;78(10):e109
pubmed: 30127056
Arthritis Rheumatol. 2019 May;71(5):670-677
pubmed: 30474933
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Ann Rheum Dis. 2002 Apr;61(4):290-7
pubmed: 11874828
Annu Rev Clin Psychol. 2010;6:109-38
pubmed: 20192788
Ann Rheum Dis. 2005 Feb;64(2):191-5
pubmed: 15647426
Ann Rheum Dis. 2017 Jun;76(6):1057-1063
pubmed: 28031164
Arthritis Care Res (Hoboken). 2010 Jun;62(6):857-64
pubmed: 20535797
BMC Rheumatol. 2022 Nov 15;6(1):67
pubmed: 36376988
Arthritis Res Ther. 2011 Jun 08;13(3):R83
pubmed: 21651807
Ann Rheum Dis. 2018 Sep;77(9):1251-1260
pubmed: 29997112
Arthritis Care Res (Hoboken). 2010 May;62(5):647-56
pubmed: 20461786
Ann Rheum Dis. 2023 Jan;82(1):48-56
pubmed: 35260387
Joint Bone Spine. 2021 Dec;88(6):105242
pubmed: 34166795
Arthritis Care Res (Hoboken). 2017 Jan;69(1):21-27
pubmed: 27564223
Stud Hastings Cent. 1973;1(3):77-88
pubmed: 4607284
Arthritis. 2015;2015:434109
pubmed: 26266046
RMD Open. 2021 Feb;7(1):
pubmed: 33547229
Rheumatology (Oxford). 2022 Oct 6;61(10):3939-3951
pubmed: 35094044
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570
BMC Rheumatol. 2019 Aug 14;3:34
pubmed: 31428740
Ann Rheum Dis. 2016 Nov;75(11):2054-2056
pubmed: 27558985
Semin Arthritis Rheum. 2011 Feb;40(4):e2-3
pubmed: 21168188
Arthritis Care Res (Hoboken). 2015 May;67(6):865-72
pubmed: 25186344
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1505-13
pubmed: 22556121
Arthritis Res Ther. 2006;8(6):221
pubmed: 17169138
J Rheumatol. 2023 Jun;50(6):721-723
pubmed: 37003607
Intern Med J. 2007 Sep;37(9):591-600
pubmed: 17573817
Ann Intern Med. 2016 Apr 19;164(8):523-31
pubmed: 27089068
Arthritis Rheum. 2002 Aug;47(4):391-7
pubmed: 12209485
Acta Clin Croat. 2019 Mar;58(1):157-166
pubmed: 31363338
BMC Musculoskelet Disord. 2016 Aug 12;17:337
pubmed: 27515300
Best Pract Res Clin Rheumatol. 2022 Mar;36(1):101735
pubmed: 34980566